Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

Andreas G Niethammer, Heinz Lubenau, Gerd Mikus, Philipp Knebel, Nicolas Hohmann, Christine Leowardi, Philipp Beckhove, Mustafa Akhisaroglu, Yingzi Ge, Marco Springer, Lars Grenacher, Markus W Buchler, Moritz Koch, Jürgen Weitz, Walter E Haefeli, Friedrich H Schmitz-Winnenthal, Andreas G Niethammer, Heinz Lubenau, Gerd Mikus, Philipp Knebel, Nicolas Hohmann, Christine Leowardi, Philipp Beckhove, Mustafa Akhisaroglu, Yingzi Ge, Marco Springer, Lars Grenacher, Markus W Buchler, Moritz Koch, Jürgen Weitz, Walter E Haefeli, Friedrich H Schmitz-Winnenthal

Abstract

Background: The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses Salmonella typhi Ty21a as a vector. The immune reaction elicited by VXM01 is expected to disrupt the tumor neovasculature and, consequently, inhibit tumor growth. VXM01 potentially combines the advantages of anti-angiogenic therapy and active immunotherapy.

Methods/design: This phase I trial examines the safety, tolerability, and immunological and clinical responses to VXM01. The randomized, placebo-controlled, double blind dose-escalation study includes up to 45 patients with locally advanced and stage IV pancreatic cancer. The patients will receive four doses of VXM01 or placebo in addition to gemcitabine as standard of care. Doses from 106 cfu up to 1010 cfu of VXM01 will be evaluated in the study. An independent data safety monitoring board (DSMB) will be involved in the dose-escalation decisions. In addition to safety as primary endpoint, the VXM01-specific immune reaction, as well as clinical response parameters will be evaluated.

Discussion: The results of this study shall provide the first data regarding the safety and immunogenicity of the oral anti-VEGFR-2 vaccine VXM01 in cancer patients. They will also define the recommended dose for phase II and provide the basis for further clinical evaluation, which may also include additional cancer indications.

Trial registration: EudraCT No.: 2011-000222-29, NCT01486329, ISRCTN68809279.

Figures

Figure 1
Figure 1
Dose escalating design.
Figure 2
Figure 2
Overall Study Scheme.

References

    1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186. doi: 10.1056/NEJM197111182852108.
    1. Summary of Product Characteristics of Avastin®. 2011.
    1. Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T. Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer. 2011;104(5):741–745. doi: 10.1038/sj.bjc.6606061.
    1. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–1939. doi: 10.1016/S0140-6736(11)61613-9.
    1. Kampen KR. The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology. Anticancer Drugs. 2012. [Epub ahead of print]
    1. Augustin H. Antiangiogenic tumor therapy: will it work? Trends Pharmacol Sci. 1998;19:216–222. doi: 10.1016/S0165-6147(98)01211-5.
    1. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11:805–812. doi: 10.1038/nrc3153.
    1. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Elicieri BP, Reisfeld RA. A DNA vaccine against vascular endothelial growth factor receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nature Medicine. 2002;8(12):1369–1375. doi: 10.1038/nm1202-794.
    1. Li Y, Wang MN, King K, Bassi R, Sun H, Santiago A, Hooper A, Bohlen P, Hicklin D. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med. 2002;195:1575–1584. doi: 10.1084/jem.20020072.
    1. Zuo SG, Chen Y, Wu ZP, Liu X, Liu C, Zhou YC, Wu CL, Jin CG, Gu YL, Li J, Chen XQ, Li Y, Wei HP, Li LH, Wang XC. Orally administered DNA vaccine delivery by attenuated Salmonella typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis. Biol Pharm Bull. 2010;33:174–182. doi: 10.1248/bpb.33.174.
    1. Reisfeld RA, Niethammer AG, Yunping L, Rong X. DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis. Immunol Rev. 2004;199:181–190. doi: 10.1111/j.0105-2896.2004.00137.x.
    1. Yrlid U, Wick MJ. Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells. J Exp Med. 2000;191:613–623. doi: 10.1084/jem.191.4.613.
    1. Wahdan M, Serie C, Cerisier Y. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: three-year results. J Infect Dis. 1982;145:292–295. doi: 10.1093/infdis/145.3.292.
    1. Gardlik R, Behuliak M, Palffy R, Celec P, Li CJ. Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene Ther. 2011;18:425–431. doi: 10.1038/gt.2010.176.
    1. AMG, German Drug Law. "Gesetz über den Verkehr mit Arzneimitteln. Neugefasst 12. Bundesgesetzblatt; 2005. p. 3394. last changed May 25, 2011 (BGBl I p 546). .
    1. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. Somerset West: Republic of South Africa; 1996.
    1. Verordnung über die Anwendung der Guten klinischen Praxis bei der Durchführung von klinischen Prüfungen mit Arzneimitteln zur Anwendung am Menschen (GCP-Verordnung) 2004. BGBl. I S. 2081, last changed on November 03, 2006 (BGBl. I S. 2523). .
    1. Note for Guidance on Good Clinical Practice (ICH E6 [R1]) CPMP/ICH/135/95, 1997. 2002. .
    1. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 published May 28, 2009 (v4.03:June 14, 2010) .
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026.
    1. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O’Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28:780–787. doi: 10.1200/JCO.2009.23.7537.
    1. Summary of Product Characteristics of Typhoral L®. 2008. .
    1. Guideline on Strategies to Identify and Mitigate Risks for First-In-Human Clinical Trials with Investigational Medicinal Products. EMEA/CHMP/SWP/28367/07. 2007. .
    1. Gilman R, Hornick R, Woodward W, DuPont H, Snyder M, Levine M, Libonati J. Evaluation of a UDP-Glucose-4-Epimerase mutant of Salmonella typhi as a live oral vaccine. J Infect Dis. 1977;136:717–723. doi: 10.1093/infdis/136.6.717.
    1. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17:3520–3526. doi: 10.1158/1078-0432.CCR-10-3126.
    1. Matejuk A, Leng Q, Chou S, Mixson A. Vaccines targeting the neovasculature of tumors. Vascular Cell. 2011;3:7. doi: 10.1186/2045-824X-3-7.
    1. Decoster L, Wauters I, Vansteenkiste JF. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. Ann Oncol. 2011. [Epub ahead of print]
    1. Brichard VG, Lejeune D. GSK’s antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine. 2007;25(Suppl 2):B61–B71.
    1. Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, Nakamura Y, Yamaue H. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Science. 2009.
    1. Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O’Reilly S, Chu L, Azar CA, Lopa S, Wolmark N. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11–16. doi: 10.1200/JCO.2010.30.0855.
    1. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–2483. doi: 10.1056/NEJMoa1104390.
    1. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–2496. doi: 10.1056/NEJMoa1103799.
    1. Bhan M, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet. 2005;366:749–762. doi: 10.1016/S0140-6736(05)67181-4.
    1. Hirooka Y, Itoh A, Kawashima H, Hara K, Nonogaki K, Kasugai T, Ohno E, Ishikawa T, Matsubara H, Ishigami M, Katano Y, Ohmiya N, Niwa Y, Yamamoto K, Kaneko T, Nieda M, Yokokawa K, Goto H. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas. 2009;38:69–74. doi: 10.1097/MPA.0b013e318197a9e3.
    1. Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, Okusaka T, Yamagata S, Takahashi N, Hyodo I, Takaue Y, Heike Y. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c + dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol. 2009;39:797–806. doi: 10.1093/jjco/hyp112.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi